Credit Available: 0.75 AMA PRA Category 1 credit(s)

Course Director: Andjela Drincic, MD, FACP​

Course Faculty: Archana R. Sadhu, MD, FACE

Basal insulin therapeutic inertia persists in both inpatient and outpatient settings, hindering optimal glycemic control. Delayed dosage adjustments and inadequate titration result in longer periods of hyperglycemia, more complications, and longer hospital stays. Addressing inertia requires proactive provider education, standardized protocols, and collaborative multidisciplinary teams to improve patient outcomes.

Credit Available: 0.5 AMA PRA Category 1 credit(s)

Course Director: Andjela Drincic, MD, FACP​

Course Faculty: Athena Philis-Tsimikas, MD and Archana R. Sadhu, MD, FACE

Once-weekly basal insulin formulations can significantly change type 2 diabetes management. The emerging agents can offer sustained glycemic control, reduced dosing frequency, and improved adherence. Clinical trials show comparable efficacy to daily basal insulins, with expected benefits in cardiovascular outcomes and weight management.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Andjela Drincic, MD, FACP​

Course Faculty: Athena Philis-Tsimikas, MD and Archana R. Sadhu, MD, FACE

Optimizing basal insulin from admission to discharge presents many challenges. Hospitalization requires personalized basal insulin regimens, that take into account many factors like renal function, medications and oral intake. Effective transition of care ensures continuity, minimizing hypoglycemia and hyperglycemia events, and improving overall patient outcomes through protocols and collaborative multidisciplinary teams. Join us for this important discussion and case presentations that will bring this information to life.